Rasmussen Ensefaliti
Özet
Referanslar
Rubey SM, Wirrell E, Yozawitz E et al. ILAE Classification and Definition of Epilepsy Syndromes with Onset at a Variable Age: Position Statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 Jun;63(6):1349-1397. doi: 10.1111/epi.17239.
Rasmussen T, Olzewski J, Lloydsmith D. Focal seizures due to chronic localized encephalitis. Neurology. 1958 Jun;8(6):435-45. doi: 10.1212/wnl.8.6.435.
Granata T, Andermann F. Rasmussen encephalitis. Handb Clin Neurol. 2013:111:511-9. doi: 10.1016/B978-0-444-52891-9.00054-3.
Borne A, Bertolotti MP, Sorbets SF, Bulteau C, Baciu M. Insights on cognitive reorganization after hemispherectomy in Rasmussen's encephalitis. A narrative review. Rev Neurosci. 2024 May 16. doi: 10.1515/revneuro-2024-0009.
Anderman F, Farrell K. Early onset Rasmussen's syndrome: a malignant, often bilateral form of the disorder. Epilepsy Res. 2006 Aug:70 Suppl 1:S259-62. doi: 10.1016/j.eplepsyres.2006.02.011.
Castellano JF, Meyer JA, Lado FA. A Case Series of Adult-Onset Rasmussen's Encephalitis: Diagnostic and Therapeutic Challenges. Front Neurol. 2017 Oct 25:8:564. doi: 10.3389/fneur.2017.00564.
Amrom D, Kinay D, Hart Y et al. Rasmussen encephalitis and comorbid autoimmune diseases. Neurology. 2015 Apr 21;84(16):1721. doi: 10.1212/WNL.0000000000000791
Takahashi Y. Infections as causative factors of epilepsy. Future Neurology. 2006(1):3, pages 291-302. https://doi.org/10.2217/14796708.1.3.291.
Wiendl H, Bien CG, Bernasconi P et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen’s encephalitis. Neurology. 2001 Oct 23;57(8):1511-4. doi: 10.1212/wnl.57.8.1511.
Longaretti F, Dunkley C, Varadkar S, Vargha-Khadem F, Boyd SG, Cross H. Evolution of the EEG in children with Rasmussen’s syndrome. Epilepsia. 2012 Jun 53(9):1539-1545. doi: 10.1111/j.1528-1167.2012.03565.x
Rogers SW, Andrews PI, GahringLC et al.: Autoantibodies to glutamate receptor GluR3 in Rasmussen‘s encephalitis. Science1994 Jul 29;265(5172):648-51. doi: 10.1126/science.8036512.
Tang C, Luan G, Li T. Rasmussen’s encephalitis: mechanisms update and potential therapy target. Ther Adv Chronic Dis. 2020 Nov 29:11:2040622320971413. doi: 10.1177/2040622320971413.
Takahashi Y, Mine J, Kubota Y, Yamazaki E, Fujiwara T. A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFα, and Granzyme B in CSF. https://doi.org/10.1111/j.1528-1167.2008.01977.x
Orsini A, Foiadelli T, Carli N et al. Rasmussen's encephalitis: From immune pathogenesis towards targeted-therapy. Seizure. 2020 Oct:81:76-83. doi: 10.1016/j.seizure.2020.07.023.
Yahya EH, Khadja L, Nourrelhouda, Nazik A, Latifa C, Siham EH. A Case Report of Rasmussen Encephalitis and its Stages: The Important Role of Imaging. Glob Pediatr Health. 2023; 10: 2333794X231214084.
Kumar A, Krishani H, Pande A, Jaiswal S, Meshram RJ. Rasmussen's Encephalitis: A Literary Review. Cureus. 2023 Oct; 15(10): e47698. doi: 10.7759/cureus.47698.
Lagarde S, Villeneuve N, Trebuchon A et al. Anti–tumor necrosis factor alpha therapy (adalimumab) in Rasmussen's encephalitis: An open pilot study. Epilepsia 2016 Apr;(57)6:956-966. https://doi.org/10.1111/epi.1338718.
Varghese B, Aneesh MK, Singh N, Gilwaz P. A Case of Rasmussen Encephalitis: The Differential Diagnoses and Role of Diagnostic Imaging. Oman Med J. 2014 Jan; 29(1): 67–70. doi: 10.5001/omj.2014.15
Lagarde S, Boucraut J, Bartolomei F. Medical treatment of Rasmussen's Encephalitis: A systematic review. Rev Neurol (Paris). 2022 Sep;178(7):675-691. doi: 10.1016/j.neurol.2022.01.007.
Bien CG, Gleissner U, Sassen R, Widman G, Urbach H, Elger CE. An open study of tacrolimus therapy in Rasmussen encephalitis. Neurology 2004 Jun;62(11):2106-2109. doi.org/10.1212/01.WNL.0000128044.94294.87
Bittner S, Simon OJ, Göbel K, Bien CG, Meuth SG, Wiendl H. Rasmussen encephalitis treated with natalizumab. Neurology. 2013 Jul 23;81(4):395-7. doi: 10.1212/WNL.0b013e31829c5ceb.
Andrews PI, Dichter MA, Berkovic SF, Newton MR, McNamara JO. Plasmapheresis in Rasmussen's encephalitis. Neurology. 1996 Jan;46(1):242-6. doi: 10.1212/wnl.46.1.242.23.
Granata T , Fusco L, Gobbi G et al. Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology. 2003 Dec 23;61(12):1807-10. doi: 10.1212/01.wnl.0000099074.04539.e0.
Kim J, Park EK, Shim KW, Kim DS. Hemispherotomy and Functional Hemispherectomy: Indications and Outcomes. J Epilepsy Res. 2018 Jun; 8(1): 1–5. doi: 10.14581/jer.18001.
Sharma A, Rammo R, Sarmey Y, Kondylis ED, Serletis D, Bingaman W. Disconnective hemispherotomy: technique and operative highlights . Neurosurg Focus Video. 2024 Jul 1;11(1):V13. doi: 10.3171/2024.4.FOCVID2436. eCollection 2024 Jul.
Takahashi Y, Yamazaki E, Mine J, Ohtsuka Y, Fujiwara T, Inoue Y. Immunomodulatory therapy versus surgery for Rasmussen syndrome in early childhood. Brain Dev. 2013 Sep;35(8):778-85. doi: 10.1016/j.braindev.2013.01.010.
